Research with contributors from UMCG published in The Lancet this week suggests that the optimal dosing of certain heart medications is lower for women than it is for men.
Translation by Traci White
According to reporting by RTV Noord, the researchers established that global standards for prescription for beta blockers are uniform for men and women. The Lancet paper says that the optimum dosage for women with heart failure turns out to be around 50 percent less than the current dosage guidelines recommend.
The scientists gathered data between 2010 and 2015 from patients in Asia and Europe, and found that female patients had better health outcomes when they were prescribed a lower dosage of the medication.
In the paper, the researchers stress that their findings should not be seen as carte blanche to “undertreat” women with heart failure and that more research is needed in order to determine how physiological differences between men and women could impact treating them for the condition.
Across the globe, medication and treatment trials are carried out either without disaggregating data based on male and female patients or excluding female participants altogether, which often leads to male-beneficial dosages and treatments being seen as the appropriate standard of care for all patients.